Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Secondary site: The front or outer thigh, positioned midway between the knee and the hip
Over 72 weeks, the 15 mg dose delivered a mean weight reduction of about 20.9%, and the 10 mg dose about 19.5%
The ongoing dedicated ophthalmic trial named as FOCUS study, which aims to evaluate semaglutides long-term effects on diabetic retinopathy, is now ongoing and could contribute to a comprehensive understanding of the true risk-benefit profile of these agents in patients with or at risk for diabetic retinopathy (NCT03811561) [104]
Clinical trials suggest notable results, with participants shedding 20.9% of their body weight
Recent findings also revealed concerns with the loss of skeletal muscle mass when taking GLP-1RAs with some studies reporting up to 50% of weight loss being due to decreases in muscle mass
Accordingly, the scientific community has taken an interest in studying other potential uses for these drugs, possibly including PCOS, Alzheimers, Parkinsons addiction, liver disease, and even some types of cancer
:max_bytes(150000):strip_icc()/GLP-1-Users-Disrupting-Food-Industry-FT-DGTL0126-ef7c3fcc00e8441195e909393d0d7a9c.jpg)
